PDE4 inhibitors showed a statistically significant improvement in attaining clear or almost clear skin compared to vehicle. In addition, PDE4 inhibitors demonstrated fairly negligible adverse effects and can be considered safer than topical corticosteroids and topical calcineurin inhibitors in the treatment of AD. The gene discussed is PDE4A; the disease is Alzheimer disease.